ReviewBiochemistry and biophysics reports2026
siRNA therapeutics for metabolic dysfunction-associated Steatohepatitis: Targets, delivery, clinical evidence, and translational challenges.
Review in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide. Its progressive inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), is driven by interacting genetic, metabolic, inflammatory, and fibrogenic processes that complicate therapeutic development. Small interfering RNA (siRNA) is an emerging modality for sequence-specific suppression of genetically supported targets and intracellular proteins that are difficult to modulate with conventional drugs. Chemical modification and liver-directed delivery have improved siRNA stability and hepatic exposure. However, most MASH-directed programs remain preclinical or in early clinical development, and human data have not established consistent histological benefit. Major limitations include delivery to nonparenchymal cells, inefficient endosomal escape, off-target effects, immunogenicity, and uncertain long-term safety. This review critically evaluates target selection, delivery, clinical and preclinical evidence, unsuccessful programs, competing nucleic acid modalities, and combination strategies. The clinical role of siRNA in MASH remains to be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.